This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: China Medical University. Active years: 2021.
Company Filing History:
Years Active: 2021
Title: Hsiang-Wen Lin: Innovator in Anti-Tumor Therapeutics
Introduction
Hsiang-Wen Lin is a prominent inventor based in Taichung, Taiwan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of anti-tumor agents. His innovative work focuses on creating effective treatments for cancer patients.
Latest Patents
Hsiang-Wen Lin holds a patent for "Irreversible inhibitors of pyruvate kinase M2 and the use thereof." This invention introduces a novel class of propiolylamide-based irreversible inhibitors of PKM2. The patent outlines pharmaceutical compositions and methods for inducing an anti-tumor effect in subjects suffering from tumors. The effective administration of these compounds can potentially improve treatment outcomes for cancer patients.
Career Highlights
Hsiang-Wen Lin is affiliated with China Medical University, where he conducts research and develops innovative therapeutic solutions. His work has garnered attention for its potential impact on cancer treatment. With a focus on enhancing the efficacy of anti-tumor therapies, Lin continues to push the boundaries of pharmaceutical science.
Collaborations
Hsiang-Wen Lin collaborates with esteemed colleagues, including Ching-Shih Chen and Chih-Shiang Chang. These partnerships foster a dynamic research environment that encourages the exchange of ideas and expertise.
Conclusion
Hsiang-Wen Lin's contributions to the field of anti-tumor therapeutics exemplify the importance of innovation in medicine. His patented work on irreversible inhibitors of pyruvate kinase M2 represents a significant advancement in cancer treatment strategies.